BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19254165)

  • 1. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.
    Smith WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):165-81. PubMed ID: 19254165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The latest data on posaconazole].
    Paugam A
    Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole: a broad-spectrum triazole antifungal.
    Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
    Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
    Nagappan V; Deresinski S
    Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole: clinical pharmacology and potential for management of fungal infections.
    Groll AH; Walsh TJ
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole: a new broad-spectrum antifungal agent.
    Kwon DS; Mylonakis E
    Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of posaconazole in the treatment of invasive fungal  infections.
    Mehta AK; Langston AA
    Expert Rev Hematol; 2009 Dec; 2(6):619-30. PubMed ID: 21082953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole: a next-generation triazole antifungal.
    Farowski F; Vehreschild JJ; Cornely OA
    Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
    Clark NM; Grim SA; Lynch JP
    Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole for paediatric patients: status of development and future perspectives.
    Groll AH; Lehrnbecher T
    Mycoses; 2008 Sep; 51 Suppl 2():5-11. PubMed ID: 18721328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
    Alexander BD; Perfect JR; Daly JS; Restrepo A; Tobón AM; Patino H; Hardalo CJ; Graybill JR
    Transplantation; 2008 Sep; 86(6):791-6. PubMed ID: 18813103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
    Groll AH; Walsh TJ
    Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
    Cecil JA; Wenzel RP
    Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
    Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
    Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Level of evidence for therapeutic drug monitoring of posaconazole].
    Lefeuvre S; Jelassi ML; Benlmouden A; Berge M; Le Guellec C; Billaud EM;
    Therapie; 2011; 66(2):115-22. PubMed ID: 21635858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.